Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation (TUNDRA-AF)
A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset
Sponsor: Sequel Pharmaceuticals, Inc
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Sequel Pharmaceuticals, Inc
More terminations from Sequel Pharmaceuticals, Inc
Other Atrial Fibrillation trials with similar outcome
This PHASE2 trial investigates Atrial Fibrillation and is currently terminated or withdrawn. Sequel Pharmaceuticals, Inc leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sequel Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ashkelon, Israel , Copenhagen, Denmark , Esbjerg, Denmark , Glostrup Municipality, Denmark , Haderslev, Denmark , Hellerup, Denmark , Herlev, Denmark , Hvidovre, Denmark , Kolding, Denmark , Odense, Denmark and 7 more locations